|1.||Sokolov, S F: 3 articles (01/2014 - 01/2002)|
|2.||Malkina, T A: 1 article (01/2014)|
|3.||Mironova, N A: 1 article (01/2014)|
|4.||Rakhmanova, M M: 1 article (01/2014)|
|5.||Rogova, M M: 1 article (01/2014)|
|6.||Golitsyn, S P: 1 article (01/2014)|
|7.||Bakalov, S A: 1 article (01/2014)|
|8.||Khisamutdinova, R Iu: 1 article (01/2013)|
|9.||Iunusov, M S: 1 article (01/2013)|
|10.||Iunusov, V M: 1 article (01/2013)|
01/01/2002 - "Special feature of allapinin is its high efficacy for prevention of attacks of paroxysmal atrial fibrillation."
02/01/1999 - "[Analysis of anti-arrhythmic effect of allapinin during neurogenic atrial fibrillation]."
09/01/1990 - "In atrial fibrillation, allapinine was shown to enhance rhythm by 7% and to increase cardiac output (p less than 0.05), as well as to slightly lower mean blood pressure and peripheral vascular resistance at rest. "
09/01/1990 - "The long-term allapinine use yielded good results: its efficacy was proved to be approximately equal (63% and 60%) in patients with ventricular or supraventricular extrasystoles, respectively, but it was 77% in those with paroxysmal atrial fibrillation. "
01/01/2003 - "Allapinin proved to be highly effective: ventricular ectopic activity was suppressed in 71.4% patients, atrial tachycardia paroxysms were prevented in 72.7%, paroxysms of atrial fibrillation--in 77.8%. "
|2.||Premature Cardiac Complexes (Extrasystoles)
01/01/2014 - "Allapinin, class 1C antiarrhythmic drug, is highly effective in treatment of patients with ventricular premature beats (VPB). "
01/01/2014 - "[Efficiency and safety of allapinin in short- and long-term treatment of patients with normal heart and ventricular premature beats]."
07/01/1989 - "Allapinine was found to be beneficial both in ventricular and supraventricular premature beats. "
11/01/1988 - "[Comparative study of the effectiveness of allapinin in patients with frequent and stable extrasystole]."
09/01/1988 - "Pharmacokinetics and pharmacodynamics of a new antiarrhythmic drug allapinin was studied in patients with frequent ventricular and supraventricular extrasystoles. "
01/01/1988 - "Antiarrhythmic efficacy of allapinin was assessed in 15 patients with heart failure combined with ventricular arrhythmias (48 h ECG monitoring). "
09/01/1990 - "Physical exercise was not followed by an apparent additional aggravation of myocardial contractility, which makes allapinine preferable for long-term application to preserve sinus rhythm in patients without evident signs of heart failure."
01/01/1989 - "Allapinin after i.v. bolus infusion in a dose of 30 mg is relatively quickly eliminated from blood (in patients without congestive heart failure half-elimination period is 2.4 +/- 0.5 h and clearance is 79.0 +/- 8.9 l/h) which makes a good reason for its intravenous infusion according to the scheme "load dose + drop infusion". "
01/01/1989 - "Marked heart failure in patients with acute myocardial infarction compared to patients without heart failure results in reduced elimination rate, decreased clearance, significantly increased plasma allapinin concentration which should be taken in account when choosing the regime of drug infusion. "
|4.||Cardiac Arrhythmias (Arrythmia)
01/01/1986 - "[Results of the clinical study of a new anti-arrhythmia preparation allapinin]."
09/01/1990 - "[Changes in systemic and intracardiac hemodynamics during bicycle ergometry in patients with fibrillation arrhythmia treated with allapinin before and after sinus rhythm recovery]."
09/01/1990 - "The authors summed up the practical experience gained in long-term maintenance treatment with allapinine, a new Soviet antiarrhythmic agent, given to 65 patients with various cardiac arrhythmias in the outpatient setting. "
02/01/1990 - "[Biological availability of the new anti-arrhythmia drug allapinin in a tablet form]."
01/01/1989 - "[Pharmacokinetics and pharmacodynamics of the new Russian anti-arrhythmia drug allapinin]."
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
01/01/2003 - "Antiarrhythmic activity of oral allapinin was studied in 64 patients with ischemic heart disease. "
01/01/2003 - "[Assessment of anti-arrhythmic efficacy of a domestic drug allapinin in patients with ischemic heart disease and cardiac arrhythmia]."
11/01/1991 - "[Pharmacodynamics of allapinine during long-term infusion in patients with chronic ischemic heart disease and frequent ventricular extrasystole]."
|2.||Electric Countershock (Cardioversion)